These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9964)

  • 1. Assessment of drugs in schizophrenia. Basic trial design.
    Lader M
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):375-9. PubMed ID: 9964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CATIE study.
    Teich J
    Am J Psychiatry; 2006 Mar; 163(3):554-5; author reply 555-6. PubMed ID: 16513894
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
    Schulz C; Timm J; Cordes J; Gründer G; Mühlbauer B; Rüther E; Heinze M
    Clin Trials; 2016 Jun; 13(3):251-9. PubMed ID: 27016729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia and antipsychotic somatic treatment.
    Lindström LH; Wieselgren IM
    Int J Technol Assess Health Care; 1996; 12(4):573-84. PubMed ID: 9136468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging guidelines for the use of antipsychotic polypharmacy.
    Stahl SM
    Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of drugs in schizophrenia. Discussion on basic trial design.
    Coppen A
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):381-3. PubMed ID: 791325
    [No Abstract]   [Full Text] [Related]  

  • 9. New antipsychotic medications: strategies for evaluation and selected findings.
    Schooler NR
    Schizophr Res; 1997 Oct; 27(2-3):249-59. PubMed ID: 9416654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521
    [No Abstract]   [Full Text] [Related]  

  • 11. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopharmacology: much the same.
    Grgas M; Ehret MJ
    Conn Med; 2009 May; 73(5):281-4. PubMed ID: 19441763
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of intermittent antipsychotic treatment in schizophrenia.
    Suzuki T; Nomura K; Watanabe K
    J Clin Psychiatry; 2011 Jan; 72(1):114; author reply 114-5. PubMed ID: 21272519
    [No Abstract]   [Full Text] [Related]  

  • 15. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management strategies for the treatment of schizophrenia.
    Kane JM
    J Clin Psychiatry; 1999; 60 Suppl 12():13-7. PubMed ID: 10372604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iloperidone: A new drug for the treatment of schizophrenia.
    Arif SA; Mitchell MM
    Am J Health Syst Pharm; 2011 Feb; 68(4):301-8. PubMed ID: 21289324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating characteristics of patient selection and dropout rates.
    Keith SJ
    J Clin Psychiatry; 2001; 62 Suppl 9():11-4; discussion 15-6. PubMed ID: 11379825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of drugs in schizophrenia. Discussion on diagnosis and patient selection.
    Johnson DA
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):371-3. PubMed ID: 791324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.